Vera Therapeutics’ Trutakna meets all prespecified endpoints in ORIGIN 3 IgA nephropathy trial
Bitget2026/10/22 14:05- Vera Therapeutics reported positive final ORIGIN 3 trial results for Trutakna in adults with primary IgA nephropathy.
- The treatment met all prespecified efficacy endpoints, slowing kidney function decline and reducing the risk of kidney disease progression versus placebo.
- Safety was generally comparable to placebo, with fewer serious adverse events.
- Results were presented at ASN Kidney Week 2026 on October 22 and simultaneously published in The New England Journal of Medicine.
- A supplemental biologics license application is planned for the fourth quarter of 2026, with potential full FDA approval in 2027.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
New Token Issuance for This Altcoin Could Drop by 36 Percent: Critical Vote Passes
US October ISM Manufacturing Index Expands Beyond Expectations, Output Growth Hits Strongest Level in Nearly Five Years
The Manufacturing Purchasing Managers' Index (PMI) released by the Institute for Supply Management (ISM) in the United States rose by 1 point in October to reach 55.5, marking the second highest reading in more than four years and exceeding the market expectation of 54.7. The production index recorded its best performance since the end of 2021, while the new orders index, a key indicator of demand, also reached its highest level since July.
Crypto prices
More
